Amyloidosis Market Epidemiology, Size, Trends, and Forecast 2025

 The 7 major amyloidosis markets size reached a value of US$ 5,251.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 20,697.4 Million by 2035, exhibiting a growth rate (CAGR) of 13.3% during 2025-2035.

The amyloidosis market in 2025 is thus grabbing ample attention owing to escalating cases and the therapeutic focus on advanced treatment options. Amyloidosis is a rare condition whereby abnormal protein deposits, referred to as amyloids, accumulate within organs and tissues, thereby causing their dysfunction. As awareness grows and improvements take place in diagnostic techniques, more patients become identified at early stages, thus leading to demand for efficient treatment and, in consequence, shaping growth in the global amyloidosis treatment market

Various factors relate to the growing incidence of amyloidosis. In the aging populations across the globe, a natural increase has been observed for aging-related disorders, of which are several kinds of amyloidosis. Besides, the disease is further associated with such conditions as multiple myeloma, chronic infections, and inflammatory disorders, which seem to be increasing as well. Additionally, there has been enhanced recognition of the disease and hence more and more diagnostics to pick up amyloidosis cases, which might have been missed otherwise. This posed a stronger emphasis on the need for working on early intervention and long-term disease management.

There has been increased awareness of the disease in recent times among medical professionals as well as patients with the situation. More doctors are now familiar with the symptoms-causing, for instance, fatigue, loss of weight, swelling, and irregular heartbeat, thus quickening patient referral and testing. Early diagnosis would not have been as big if not for the urgent role played by patient groups advocating for the awareness campaigns. Technological innovations are ushering in a welcome change in the diagnosis and treatment of amyloidosis. New imaging technologies, such as sophisticated MRI and PET scans, provide clear images of organ involvement. Next-generation sequencing and mass spectrometry are also increasingly useful for precise identification of the type of amyloid protein, essential in selecting treatment. Such diagnostic advancements are making treatment more targeted and personalized for patients.

The therapeutic arena is also changing at a very fast pace. Old therapies that focused primarily on symptom management and disease slowing are now complemented by newer interventions. New therapies that target fewer proteins or assist with clearance of the proteins from the body are currently emerging. New-generation drugs are under development that stabilize the proteins used in amyloid formation or degrade deposits already formed. This is creating new avenues for patients who had few treatment options in the past. One of the major areas of progress in 2025 is the creation of targeted therapies for individual subtypes of amyloidosis, including AL amyloidosis and ATTR amyloidosis. Drug companies are pumping money into clinical trials, and a number of promising treatments are in the pipeline or awaiting approval. These new therapies are likely to make a huge difference in survival rates and quality of life for patients.

Request for a sample of this report: https://www.imarcgroup.com/amyloidosis-market/requestsample

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the amyloidosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the amyloidosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current amyloidosis market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the amyloidosis market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Alnylam Pharmaceuticals

2. Akcea Therapeutics/Ionis Pharmaceuticals

3. Alnylam Pharmaceuticals

4. Pfizer

5. Janssen Biotech

6. Prothena

7. Zentalis Pharmaceuticals

8.Sorrento Therapeutics

9. Attralus

10. Caelum Biosciences

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=7094&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145